Evotec SE (EVO) Q3 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call summary reveals several negative aspects: a 7% decline in group revenues, negative EBITDA, and economic uncertainties. The Q&A highlights concerns about market recovery, profitability, and management's unclear responses. Despite some positive aspects like JEB growth and strategic transactions, the overall sentiment remains negative due to the revenue decline and financial challenges. The market cap indicates a small-cap company, which typically reacts more strongly to negative news, supporting a prediction of a negative stock price movement (-2% to -8%) over the next two weeks.

Key Financial Performance

Group revenues EUR 535.1 million, a 7% decline year-over-year. The decline is driven by the D&PD business, which faced a 12% revenue decline due to continued softness in the early drug discovery market.

D&PD revenues EUR 391.9 million, a 12% decline year-over-year. This decline is attributed to a persisting soft market in early drug discovery and temporary decline in BMS revenues.

Just-Evotec Biologics revenues EUR 143.2 million, an 11% increase year-over-year. Growth is attributed to a broadening customer base, with non-Sandoz and non-DoD customers growing 105% year-over-year.

R&D spending EUR 27.7 million, a 33% reduction year-over-year. The reduction is due to directing investments to areas most relevant for partners.

Adjusted Group EBITDA Negative EUR 16.9 million, driven by weaker D&PD revenues and a fixed cost base.

Free cash flow Improved by 14% year-over-year despite tough comparables from the previous year.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

Biologics business growth: Just-Evotec Biologics (JEB) achieved 11% growth in the first 9 months of 2025. The business development within non-Sandoz and non-DoD customers grew over 100%.

New molecules in clinical trials: Up to 4 molecules from the partnered asset pipeline are expected to be in Phase II clinical studies in 2026.

AI-driven platforms: Evotec's AI-driven platforms have been integrated into drug discovery processes, improving outcomes and reducing timelines. These platforms have generated over $200 million in order value.

Sandoz partnership: A transformational deal with Sandoz was signed, unlocking payments of more than $650 million over the next years and royalty streams from 10 biosimilars.

Expansion in biologics market: Evotec's biologics business is diversifying its customer portfolio and expanding its market presence, with significant growth in non-Sandoz and non-DoD business.

Cost reduction initiatives: Evotec raised its cost reduction target to EUR 60 million for 2025 and is ahead of plan. An additional EUR 50 million in cost-out and productivity measures is planned.

Improved operational structure: A new organizational structure was introduced, strengthening commercial and operational capabilities.

Shift to asset-lighter model: Evotec is transitioning to an asset-lighter, higher-margin business model, focusing on technology licensing and partnerships rather than direct manufacturing.

Focus on technology leadership: The company is leveraging its proprietary AI and biologics platforms to drive innovation and create value through strategic partnerships.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Decline in Group Revenues: Group revenues declined by 7% year-over-year, primarily driven by a 12% revenue decline in the D&PD business due to continued softness in the early drug discovery market.

Early Drug Discovery Market Challenges: The early drug discovery market is facing unfavorable VC funding conditions, impacting approximately 30%-40% of the company's revenue base in D&PD. This has led to reduced business development activities and higher-than-expected contract cancellations.

Cost Base Adjustments: The company has had to implement significant cost-out measures, targeting EUR 60 million in 2025, with plans for an additional EUR 50 million in cost reductions. This reflects challenges in maintaining profitability amidst declining revenues.

Customer Contract Cancellations: Higher-than-expected cancellations of contracts in the first half of 2025, due to strategic or scientific reasons, negatively impacted sales performance in the D&PD segment.

Regulatory and Transactional Risks: The sale of the Just-Evotec Biologics' Toulouse site to Sandoz is subject to regulatory approvals, including foreign direct investment clearance by French authorities, which could delay or complicate the transaction.

Economic and Market Uncertainty: The broader economic environment, including the lack of recovery in VC funding for early-stage biotech, continues to pose risks to the company's growth and revenue stability.

Fixed Cost Base Impact: The company's fixed cost base has contributed to a negative adjusted Group EBITDA of EUR 16.9 million, exacerbated by weaker-than-expected D&PD revenues.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

D&PD Business Outlook: The company expects the trend of softness in the early drug discovery market to continue in the second half of 2025. However, there are signs of stabilization with an upward trend in the number and value of proposals to customers. The company remains vigilant and is strengthening its commercial organization to adapt to evolving customer needs.

Just-Evotec Biologics Growth: Revenue growth is expected to further accelerate, with non-Sandoz and non-DoD business growing over 100% after 9 months. A transformational deal with Sandoz is expected to unlock payments of more than $650 million over the next years, along with sizable revenues from royalty streams related to 10 biosimilars.

Cost Reduction Initiatives: The company is on track to deliver EUR 60 million of cost reductions in 2025 and is working on an additional EUR 50 million of cost-out and productivity measures for the future.

Asset Pipeline Progression: The company expects up to 4 molecules from its partnered asset pipeline to be in Phase II clinical studies in 2026, demonstrating scientific strength and potential for milestone and royalty payments.

Mid-Term Financial Goals: The company confirms its guidance for 2025 with targeted revenue of EUR 760 million to EUR 800 million and an expected adjusted EBITDA in the range of EUR 30 million to EUR 50 million. Mid-term goals include 8% to 12% top-line growth and EBITDA margins greater than 20%.

Sandoz Transaction Impact: The sale of the Just-Evotec Biologics' Toulouse site to Sandoz is expected to provide an initial consideration of about $350 million, with additional mid-term revenues from licenses, development services, and milestones exceeding $300 million. Long-term royalty payments are anticipated for up to 10 molecules.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:How much were Sandoz revenues in the first 9 months, and what would the division have looked like without the Sandoz revenues and associated costs in Toulouse?

A:Non-Sandoz revenue year-to-date was over 50% of the overall year-to-date revenue. The Toulouse build-out cost was around EUR 20 million, providing a view of normalized share and profitability for the division.

Q:How much of the EUR 30 million to EUR 50 million EBITDA guide for this year is the expected upfront recognition from the Sandoz deal?

A:The license recognition from Sandoz is included within the initial $350 million upfront payment, but the company is not splitting out the license component within that amount.

Q:What is the revenue trajectory from 2025 to 2028, and how lumpy might it be depending on milestones?

A:The revenue CAGR is expected to be on the lower end of the 10%-12% range, with stronger potential on EBITDA margin rate. Milestones are expected to be lumpy, with 2/3 of the consideration between 2026 and 2028 being product development activity and 1/3 being licenses and milestones.

Q:To what extent do NAMs capabilities come up in conversations with partners and customers, and how might they help grow revenues over the next 12 to 18 months?

A:NAMs are gaining more attention, particularly from pharma, with signs of acceleration as projects integrate NAMs earlier in the process. Revenues from NAMs are expected to accelerate within the next 12 to 24 months.

Q:What is the outlook for the drug discovery and preclinical development segment into 2026, and is 5% growth for next year a sensible starting point?

A:The company has limited visibility into 2026 and is cautious about making statements on market recovery. While there are green shoots, the company is not committing to a 5% growth estimate for next year.

Q:Why was profitability in the Discovery & Preclinical Development segment weaker in Q3 despite stable revenues?

A:The first half had better mix and a license benefit that did not repeat in Q3. Milestone recognition volatility continues to impact this segment.

Q:How does the Sandoz deal compare to previous CDMO income streams, and is the EUR 420 million consensus for JEB business in 2028 accurate?

A:The Sandoz deal shifts the business model to a more capital-efficient license model, improving gross margins. While there is some revenue reduction, the higher quality revenue mix supports the business. The EUR 420 million consensus for 2028 is not explicitly confirmed or denied.

Q:What are customers saying about the current market environment, and what are the implications for pricing?

A:Customers are cautious, with slower decision-making and smaller projects. Pricing is affected by overcapacity in the market, but normalization is expected as demand and capacity balance.

Q:Are there geographic variations in market performance?

A:Yes, the U.S. market showed less dynamic performance earlier in the year, while the European market showed more activity. There is variation depending on subsegments.

Q:Review of Unclear Management Responses

A:Management avoided directly addressing the specific split of the license component within the $350 million upfront payment from the Sandoz deal. Additionally, they did not confirm or deny the accuracy of the EUR 420 million consensus for the JEB business in 2028, leaving some ambiguity.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

EVO Transcript

Evotec SE (EVO) Q3 2025 Earnings Call Transcript

Unknown11-5

Evotec SE (EVO) Q2 2025 Earnings Call Transcript

Unknown8-13

The earnings call presents a mixed picture. Strong partnerships and technology leadership are positive, but management's reluctance to provide specifics in the Q&A raises concerns. While strategic partnerships and AI integration are promising, the lack of concrete guidance and details, particularly regarding the Sandoz deal and revenue specifics, may temper enthusiasm. Additionally, the market cap suggests moderate sensitivity to these factors. Overall, the sentiment is balanced, leading to a neutral prediction for stock movement.

Evotec SE (NASDAQ:EVO) Q1 2025 Earnings Call Transcript

Unknown5-7

The earnings call indicates a negative sentiment due to several factors: declining revenues in Shared R&D, increased net debt, and cost management challenges. Although there is some optimism for mid-term recovery, the lack of a shareholder return plan and unclear management responses in the Q&A add to the uncertainty. While there is a slight improvement in EPS, the overall financial performance and market dynamics suggest a negative impact on the stock price, particularly for a small-cap company.

Evotec SE (EVO) Q1 2025 Earnings Call Transcript

Unknown5-6

The earnings call reveals several concerning factors: a revenue decline in Shared R&D, increased net debt, and cost management challenges. Despite optimistic guidance, the lack of shareholder return plans and unclear management responses in the Q&A section further dampen sentiment. The market cap of €1.6 billion suggests a moderate reaction, leading to a predicted stock movement in the negative range of -2% to -8%.

EVO Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.